Wolfgang Schreiner
Overview
Explore the profile of Wolfgang Schreiner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
46
Citations
535
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Schreiner W, Karch R, Cibena M, Tomasiak L, Kenn M, Pfeiler G
Comput Struct Biotechnol J
. 2023 Aug;
21:3920-3932.
PMID: 37602229
Molecular mechanisms within the checkpoint receptor PD-1 are essential for its activation by PD-L1 as well as for blocking such an activation via checkpoint inhibitors. We use molecular dynamics to...
2.
Kenn M, Karch R, Singer C, Dorffner G, Schreiner W
J Pers Med
. 2023 Jan;
13(1).
PMID: 36675780
Evidence theory by Dempster-Shafer for determination of hormone receptor status in breast cancer samples was introduced in our previous paper. One major topic pointed out here is the link between...
3.
Kenn M, Karch R, Tomasiak L, Cibena M, Pfeiler G, Koelbl H, et al.
Front Bioeng Biotechnol
. 2022 Oct;
10:838129.
PMID: 36277392
Cells in danger of being erroneously attacked by leucocytes express PD-L1 on their surface. These cells activate PD-1 on attacking leucocytes and send them to death, thus curbing erroneous, autoimmune...
4.
Koller S, Kendler J, Karacs J, Wolf A, Kreuzinger C, von der Decken I, et al.
Front Pharmacol
. 2022 Sep;
13:946348.
PMID: 36105223
Patients with high-grade serous ovarian cancer (HGSOC) have a very poor overall survival. Current therapeutic approaches do not bring benefit to all patients. Although genetic alterations and molecular mechanisms are...
5.
Tomasiak L, Karch R, Schreiner W
BMC Immunol
. 2022 Jul;
23(Suppl 1):36.
PMID: 35902791
Background: Major histocompatibility complexes (MHCs) play a crucial role in the cell-mediated adaptive immune response as they present antigenic peptides (p) which are recognized by host T cells through a...
6.
Kenn M, Karch R, Cacsire Castillo-Tong D, Singer C, Koelbl H, Schreiner W
J Pers Med
. 2022 Apr;
12(4).
PMID: 35455687
Estrogen and progesterone receptors being present or not represents one of the most important biomarkers for therapy selection in breast cancer patients. Conventional measurement by immunohistochemistry (IHC) involves errors, and...
7.
Pichler K, Fischer A, Alphonsus J, Chiari C, Schmidt S, Kenn M, et al.
Histochem Cell Biol
. 2021 Nov;
157(2):139-151.
PMID: 34846578
Galectin-4 (Gal-4) is a member of the galectin family, which have been identified as galactose-binding proteins. Gal-4 possesses two tandem repeat carbohydrate recognition domains and acts as a cross-linking bridge...
8.
Kenn M, Cacsire Castillo-Tong D, Singer C, Karch R, Cibena M, Koelbl H, et al.
Sci Rep
. 2021 Feb;
11(1):4233.
PMID: 33608588
Correctly estimating the hormone receptor status for estrogen (ER) and progesterone (PGR) is crucial for precision therapy of breast cancer. It is known that conventional diagnostics (immunohistochemistry, IHC) yields a...
9.
Roither B, Oostenbrink C, Pfeiler G, Koelbl H, Schreiner W
Cancers (Basel)
. 2020 Dec;
13(1).
PMID: 33375020
To improve cancer immunotherapy, a clearer understanding of key targets such as the immune checkpoint receptor PD-1 is essential. The PD-1 inhibitors nivolumab and pembrolizumab were recently approved by the...
10.
Gruber E, Oberhuber G, Birner P, Schlederer M, Kenn M, Schreiner W, et al.
Cells
. 2020 Dec;
9(12).
PMID: 33371531
The authors wish to make the following change to their paper [...].